Brooks Laboratories Ltd Incorporates Wholly Owned Subsidiary ABRIDGE SPECIALITY LIMITED for Strategic Expansion
Brooks Laboratories Limited has announced the incorporation of a wholly owned subsidiary, ABRIDGE SPECIALITY LIMITED, effective July 2, 2026. The new entity is set up to support the Company's strategic objective of expanding its business within the pharmaceutical sector.The newly established Wholly Owned Subsidiary (WOS) falls under the Manufacturing and Marketing of Pharmaceuticals and related products industry. Brooks Laboratories Limited holds a 100% shareholding in ABRIDGE SPECIALITY LIMITED, making it a Related Party to the parent company.
Details regarding the subsidiary’s incorporation and structure are as follows:
| Particulars | Details |
|---|---|
| Subsidiary Name | ABRIDGE SPECIALITY LIMITED |
| Date of Incorporation | July 2, 2026 |
| Industry | Manufacturing and Marketing of Pharmaceuticals and related products |
| Authorized Share Capital | Rs. 1,00,000 (Rupees One Lakh) |
| Ownership Percentage | 100% |
The incorporation of ABRIDGE SPECIALITY LIMITED aligns with the Company's broader strategic goal to scale its operations and enhance its business presence in the pharmaceutical market. The initial share capital for the subsidiary was subscribed at face value upon incorporation, as the entity is yet to commence its commercial operations. As a recently incorporated company, ABRIDGE SPECIALITY LIMITED does not have prior turnover history.
BROOKS Stock Price Movement
Today, shares of Brooks Laboratories Limited edged higher to close at ₹75.91 after gaining 4.99%, reflecting strong activity in the pharmaceutical sector. The stock traded a volume of 48,299 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.